MCID: NRG002
MIFTS: 55

Neurogenic Bladder

Categories: Nephrological diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Bladder

MalaCards integrated aliases for Neurogenic Bladder:

Name: Neurogenic Bladder 12 29 6 15
Neurogenic Dysfunction of the Urinary Bladder 12
Neurogenic Urinary Bladder Disorder 12
Urinary Bladder, Neurogenic 44
Neurogenic Urinary Bladder 72
Neuropathic Bladder 12
Bladder Neurogenic 55

Classifications:



External Ids:

Disease Ontology 12 DOID:12143
ICD9CM 35 596.54
MeSH 44 D001750
NCIt 50 C79696
SNOMED-CT 68 23201000
UMLS 72 C0005697

Summaries for Neurogenic Bladder

MalaCards based summary : Neurogenic Bladder, also known as neurogenic dysfunction of the urinary bladder, is related to lethal congenital contracture syndrome 2 and low compliance bladder, and has symptoms including seizures, vertigo and pain. An important gene associated with Neurogenic Bladder is EBF3 (EBF Transcription Factor 3), and among its related pathways/superpathways are Calcium signaling pathway and Arf6 trafficking events. The drugs Lidocaine and Oxybutynin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, prostate and kidney, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia : 75 Neurogenic bladder dysfunction, sometimes simply referred to as neurogenic bladder, is a dysfunction of... more...

Related Diseases for Neurogenic Bladder

Diseases related to Neurogenic Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 338)
# Related Disease Score Top Affiliating Genes
1 lethal congenital contracture syndrome 2 32.2 PIP5K1C ERBB3
2 low compliance bladder 30.4 P2RX2 CHRM2
3 hinman syndrome 11.9
4 urofacial syndrome 1 11.8
5 sacral defect with anterior meningocele 11.6
6 polyglucosan body neuropathy, adult form 11.4
7 adult polyglucosan body disease 11.4
8 lateral meningocele syndrome 11.3
9 lethal congenital contracture syndrome 3 11.3
10 peroxisome biogenesis disorder 10b 11.3
11 leukodystrophy, progressive, early childhood-onset 11.3
12 giant axonal neuropathy 11.3
13 cog5-congenital disorder of glycosylation 11.3
14 spinal cord injury 11.0
15 acute cystitis 10.8
16 myelomeningocele 10.8
17 neural tube defects 10.8
18 vesicoureteral reflux 1 10.7
19 hydronephrosis 10.7
20 detrusor sphincter dyssynergia 10.7
21 bacteriuria 10.6
22 pyelonephritis 10.5
23 bladder disease 10.5
24 cystitis 10.4
25 paraplegia 10.4
26 spasticity 10.4
27 constipation 10.4
28 multiple sclerosis 10.3
29 pyuria 10.3
30 bladder cancer 10.3
31 prostatic hypertrophy 10.3
32 urinary tract obstruction 10.3
33 herpes zoster 10.3
34 quadriplegia 10.3
35 myelitis 10.3
36 kidney disease 10.3
37 lipomatosis, multiple 10.2
38 pleomorphic lipoma 10.2
39 neuropathy 10.2
40 impotence 10.2
41 end stage renal failure 10.2
42 spinal shock 10.2
43 prostatic hyperplasia, benign 10.2
44 hydrocephalus 10.2
45 urethral stricture 10.2
46 cerebral palsy 10.2
47 prostatic adenoma 10.2
48 spinal cord disease 10.2
49 47,xyy 10.2
50 48,xyyy 10.2

Comorbidity relations with Neurogenic Bladder via Phenotypic Disease Network (PDN): (show all 27)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Bladder Neck Obstruction Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Hypertension, Essential
Hypothyroidism Multiple Sclerosis
Osteoporosis Paralytic Ileus
Paraplegia Parkinson Disease, Late-Onset
Peripheral Vascular Disease Prostatic Hypertrophy
Protein-Energy Malnutrition Schizophreniform Disorder
Swallowing Disorders Transient Cerebral Ischemia
Urethral Stricture

Graphical network of the top 20 diseases related to Neurogenic Bladder:



Diseases related to Neurogenic Bladder

Symptoms & Phenotypes for Neurogenic Bladder

UMLS symptoms related to Neurogenic Bladder:


seizures, vertigo, pain, dysuria, meningism, reflex, abnormal, urgency of micturition, neurobehavioral manifestations, neuromuscular manifestations

MGI Mouse Phenotypes related to Neurogenic Bladder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.61 ACER3 CACNA1A CHRM2 ERBB3 GBE1 HPSE2
2 nervous system MP:0003631 9.23 ACER3 CACNA1A CHRM2 EBF3 ERBB3 GBE1

Drugs & Therapeutics for Neurogenic Bladder

Drugs for Neurogenic Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
3
Silodosin Approved Phase 4 160970-54-7
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Belladonna Approved, Experimental Phase 4
6
Mirabegron Approved Phase 4 223673-61-8 9865528
7
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
8
Cefixime Approved, Investigational Phase 4 79350-37-1 54362 5362065
9
Fosfomycin Approved Phase 4 23155-02-4 446987
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
12
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
13
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
14
Fidaxomicin Approved Phase 4 873857-62-6
15
Vancomycin Approved Phase 4 1404-90-6 441141 14969
16 Parasympatholytics Phase 4
17 Neurotransmitter Agents Phase 4
18 Cholinergic Agents Phase 4
19 Muscarinic Antagonists Phase 4
20 Cholinergic Antagonists Phase 4
21 Autonomic Agents Phase 4
22 Adrenergic alpha-1 Receptor Antagonists Phase 4
23 Adrenergic Agents Phase 4
24 Renal Agents Phase 4
25 Mandelic Acids Phase 4
26 Anti-Infective Agents, Urinary Phase 4
27 Analgesics Phase 4
28 Opiate Alkaloids Phase 4
29 Narcotics Phase 4
30 Central Nervous System Depressants Phase 4
31 Analgesics, Opioid Phase 4
32 Gentamicins Phase 4
33 Adrenergic Agonists Phase 4
34 Adrenergic beta-Agonists Phase 4
35 Adrenergic beta-3 Receptor Agonists Phase 4
36 Antibiotics, Antitubercular Phase 4
37 Antitubercular Agents Phase 4
38 Solifenacin succinate Phase 4 242478-38-2
39 penicillins Phase 4
40 Cola Phase 4
41 Bifidobacterium Phase 4
42 Anti-Infective Agents Phase 4
43 Anti-Bacterial Agents Phase 4
44
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
45
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
46
Tamsulosin Approved, Investigational Phase 2, Phase 3 106133-20-4 129211
47
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
48
Ofloxacin Approved Phase 3 82419-36-1 4583
49
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
50
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
2 Randomized Placebo-Controlled Trial of Gentamicin Bladder Instillation for the Prevention of Urinary Tract Infection in Adults at High Risk for Cystitis Due to Intermittent Catheterization Unknown status NCT01884467 Phase 4 Gentamicin;Placebo
3 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Unknown status NCT02298660 Phase 4 BOTOX
4 A 12-week, Open-label, Multi-center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder Completed NCT01228370 Phase 4 silodosin
5 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial) Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
6 Quality of Life Intermittent Catheter Study - A Prospective, Randomized, Cross-over, Multicenter Study Comparing Quality of Life Using Compact Versus Standard Urinary Intermittent Catheters Completed NCT01523743 Phase 4
7 A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
8 A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
9 Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy Completed NCT01421719 Phase 4 Cystoscopic injection of Botox into the urinary bladder
10 A Prospective, Randomized, Parallel-group, Multi-center Study to Compare the Occurrence of Urinary Tract Infections in Patients With Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters. Completed NCT00318591 Phase 4
11 A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury Completed NCT00224029 Phase 4 Oxybutynin transdermal system
12 Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome (Cts): A Randomized, Placebo-Controlled Trial With Secondary Bayesian Modification Completed NCT00277563 Phase 4
13 The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1 Completed NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
14 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
15 A Two-part, Multicenter, Dose-titration Study Evaluating Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for Treatment of Detrusor Overactivity Associated Neurological Condition in Pediatric Patients Recruiting NCT01192568 Phase 4 Oxybutynin
16 Use of Novel Human Milk Prebiotics to Improve the Quality of Life for Spinal Cord Injury Patients With Bowel and Bladder Dysfunction Not yet recruiting NCT03987126 Phase 4
17 Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
18 Antiseptic-coated Intermittent Urinary Catheter: Efficacy and Feasibility of Neurogenic Bladder Management and Prevention of Catheter-associated Urinary Tract Infections in Children Unknown status NCT02697162 Phase 2, Phase 3 Octenidine chloride
19 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
20 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
21 A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04) Unknown status NCT01050114 Phase 3 onaBoNT-A;Oxybutynin ER
22 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
23 A Phase IIb/III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Dose Ranging Study of Tamsulosin Hydrochloride (Low, Medium and High Dose) as Treatment in Children With Neuropathic Bladder for Three Months Completed NCT00796614 Phase 2, Phase 3 tamsulosin hydrochloride;Placebo
24 A Pilot Study Comparing the Effects of Botulinum Toxin A and Standard Oxybutynin Therapy as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Completed NCT01716624 Phase 3 Oxybutynin;Botulinum Toxin A injection
25 Four-week, Open-label, Multicenter, Randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety, Tolerability and the Effects on Leak Point Pressure of Two Oral Doses of Alfuzosin (0.1 mg/kg/Day; 0.2 mg/kg/Day) in Children and Adolescents 2 to 16 Years-of-age With Elevated Detrusor Leak-point Pressure of Neuropathic Etiology Completed NCT00629720 Phase 3 alfuzosin (SL770499)
26 12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension Completed NCT00549939 Phase 3 Alfuzosin;Placebo
27 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed NCT01600716 Phase 3 Placebo (Normal Saline)
28 12-week, Multicenter, Open-label, Non-comparative Study to Investigate Pharmacodynamic and Safety of Alfuzosin 0.2 mg/kg/Day in the Treatment of Children and Adolescents 2 - 16 Years of Age With Hydronephrosis Associated With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension Completed NCT00576823 Phase 3 Alfuzosin
29 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
30 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
31 Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients. Completed NCT00280592 Phase 3 Cranberry;Placebo
32 A 24-WEEK RANDOMIZED, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) Recruiting NCT01557244 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine PR 8 mg;Oxybutynin;Fesoterodine PR;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
33 Oxybutynin for Post-surgical Bladder Pain and Urgency Recruiting NCT03952299 Phase 3 Oxybutynin Transdermal Patch;Oral Oxybutynin
34 LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVERACTIVITY) WHO HAVE COMPLETED 24 WEEKS TREATMENT IN STUDY A0221047 Recruiting NCT02501928 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
35 Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS) Not yet recruiting NCT03774407 Phase 2, Phase 3 vaginal estriol
36 The Effect of Gentamicin Intravesical Installations on Decreasing Urinary Tract Infections in Patients With Neurogenic Bladder After Spinal Cord Injury: A Clinical Trial Suspended NCT03503513 Phase 2, Phase 3 Gentamicin Sulfate;Saline
37 A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients Terminated NCT02044510 Phase 2, Phase 3 Mirabegron;Placebo
38 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
39 Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction Unknown status NCT00602186 Phase 1, Phase 2 tamsolusin;prazosin
40 Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study Unknown status NCT02591901 Phase 2 Uro vaxom
41 A Clinical Trial to Determine the Extent to Which Probiotic Therapy Reduces Side Effects of Antibiotic Prophylaxis in Pediatric Neurogenic Bladder Patients With a History of Recurrent Urinary Tract Infections Unknown status NCT02044965 Phase 1, Phase 2 Probiotic
42 An Uncontrolled, Open-label, Titration, Long-term Safety (up to 12 Months) and Efficacy Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder, With a Randomized Pharmacokinetic Sub-study Investigating Low, Medium and High Dose Ranges. Completed NCT00340704 Phase 2 tamsulosin hydrochloride
43 Self-management of Urine Flow in Long-term Urinary Catheter Users Completed NCT00883220 Phase 2
44 Multifaceted Treatment of Catheter-related Urinary Tract Infection Completed NCT00732238 Phase 2
45 A Multicenter, Double-blind, Crossover Design, Pilot Study to Evaluate the Effect of NVC-422 Catheter Irrigation on Urinary Catheter Patency Completed NCT01243125 Phase 2 NVC-422, 0.2%;Sterile normal saline, 0.9%
46 Lumbar to Sacral Ventral Nerve Re-Routing Completed NCT00378664 Phase 2
47 A Treatment Trial of Triheptanoin in Patients With Adult Polyglucosan Body Disease - A Randomized Controlled Study Completed NCT00947960 Phase 2 Triheptanoin
48 UTI Prophylaxis Using Bacterial Interference Following SCI Completed NCT00037921 Phase 2
49 Comparison of the Therapeutic Effects of Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome Completed NCT01657409 Phase 2 BoNT-A (10 injection);BoNT-A (20 injection);BoNT-A (40 injection)
50 Comparative Study of Safety and Efficacy Between 100 U Suburothelial Injection and 50 U Suburothelial Plus 50 U Urethral Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility Completed NCT02135341 Phase 2 Botulinum toxin A;Botulinum toxin A

Search NIH Clinical Center for Neurogenic Bladder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Baclofen
Bethanechol
Bethanechol
Bethanechol Chloride
Hyoscyamine
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
oxybutynin
Oxybutynin
Oxybutynin chloride

Cochrane evidence based reviews: urinary bladder, neurogenic

Genetic Tests for Neurogenic Bladder

Genetic tests related to Neurogenic Bladder:

# Genetic test Affiliating Genes
1 Neurogenic Bladder 29

Anatomical Context for Neurogenic Bladder

MalaCards organs/tissues related to Neurogenic Bladder:

41
Spinal Cord, Prostate, Kidney, Brain, Testes, Colon, Heart

Publications for Neurogenic Bladder

Articles related to Neurogenic Bladder:

(show top 50) (show all 3947)
# Title Authors PMID Year
1
Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. 9 38
12783571 2003
2
Hydrocephalus associated with multiple Tarlov cysts. 38
31383334 2019
3
The Connected Catheter for management of Chronic Urinary Retention (CUR) in an adult male with Neurogenic Bladder - Case study. 38
31297331 2019
4
Patient Reported Bladder Related Symptoms and Quality of Life after Spinal Cord Injury with Different Bladder Management Strategies. 38
30958741 2019
5
Outcomes of renal calculi in patients with spinal cord injury. 38
31297852 2019
6
Interferential electrical stimulation for improved bladder management following spinal cord injury. 38
31423306 2019
7
Pyuria as a Marker of Urinary Tract Infection in Neurogenic Bladder: Is It Reliable? 38
31261361 2019
8
Create a predictive model for neurogenic bladder patients: upper urinary tract damage predictive nomogram. 38
31401918 2019
9
Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Five-Year Experience of a Retrospective, Multicenter Study in China. 38
30609180 2019
10
Safety, Feasibility, and Efficacy of Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury Neurogenic Bladder: A Randomized Control Pilot Trial. 38
30284350 2019
11
Patient subjective assessment of urinary tract infection frequency and severity is associated with bladder management method in spinal cord injury. 38
30872758 2019
12
Outcomes of Endourologic Interventions in Patients with Preoperative Funguria. 38
30924689 2019
13
[A survey of risk factors and quality of life in female medical staff with urinary incontinence]. 38
31420626 2019
14
Neurogenic bladder in an adolescent woman with an ovarian tumour: an unusual presentation of anti-NMDA-receptor encephalitis. 38
31383677 2019
15
Nursing Care of the Patient With Neurogenic Bladder After Kidney Transplantation: A Case Report. 38
31405733 2019
16
Health-related quality of life in paediatric spina bifida. 38
31424034 2019
17
Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. 38
30511212 2019
18
Are EAU/ESPU pediatric urology guideline recommendations on neurogenic bladder well received by the patients? Results of a survey on awareness in spina bifida patients and caregivers. 38
31102557 2019
19
A new bladder-emptying method in females with neurogenic bladder: A randomized, phase II trial. 38
31165506 2019
20
The role of appetite-regulating hormones: Ghrelin and leptin in the nutritional status of children with neurogenic bladder due to myelomeningocele. 38
30488610 2019
21
Validity of a disposable catheter to drain urine overnight in neurogenic bladder. 38
30779413 2019
22
A Retrospective Case Series of High-Frequency Spinal Cord Stimulation (HF10-SCS) in Neurogenic Bladder Incontinence. 38
30169840 2019
23
A nonsurgical and nonpharmacological care bundle for preventing upper urinary tract damage in patients with spinal cord injury and neurogenic bladder. 38
31328348 2019
24
A systematic review of the content and quality of clinical practice guidelines for management of the neurogenic bladder following spinal cord injury. 38
30971756 2019
25
Differential neurodegenerative phenotypes are associated with heterogeneous voiding dysfunction in a coronavirus-induced model of multiple sclerosis. 38
31350464 2019
26
Vesicostomy button: how is it placed, in whom, and how is quality of life affected? 38
31063284 2019
27
Low Interrater Reliability of Videourodynamic Diagnosis of Detrusor External Sphincter Dyssynergia. 38
31295186 2019
28
Performance of a Natural Language Processing Method to Extract Stone Composition From the Electronic Health Record. 38
31310771 2019
29
Validation of Upper Extremity Motor Function as a Key Predictor of Bladder Management After Spinal Cord Injury. 38
31348899 2019
30
Lumbosacral radicular pain during micturition, defecation or orgasm. 38
30697909 2019
31
Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial. 38
30814670 2019
32
Avoiding the Need for Bowel Anastomosis during Pelvic Exenteration-Urinary Sigmoid or Descending Colon Conduit-Short and Long Term Complications. 38
30922975 2019
33
Nonsecretory intestinocystoplasty: postoperative outcomes of 25 years. 38
31184453 2019
34
Endoscopic fetal surgery for neural tube defects. 38
31350160 2019
35
[Interest of transcranial stimulation in pelvic and perineal disorders]. 38
31036483 2019
36
Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer. 38
31351675 2019
37
Ureteric implantation into the bowel portion of augmented bladders during kidney transplantation: a review of urological complications and outcomes. 38
30685889 2019
38
Hypertensive urgency in nephrogenic diabetes insipidus with concomitant Hinman syndrome. 38
31352377 2019
39
Bladder Augmentation (Enterocystoplasty): the Current State of a Historic Operation. 38
31342172 2019
40
Randomized Clinical Trial Using Sterile Single Use and Reused Polyvinylchloride Catheters for Intermittent Catheterization with a Clean Technique in Spina Bifida Cases: Short-Term Urinary Tract Infection Outcomes. 38
30916625 2019
41
[Spinal cord injury with neurogenic lower urinary tract dysfunction as a potential risk factor for bladder carcinoma]. 38
29843184 2019
42
[Spanish consensus document for the diagnosis, treatment and management of neurogenic bladder.] 38
31223126 2019
43
Reliability and Validity of the Neurogenic Bladder Symptom Score in Adults with Cerebral Palsy. 38
30890419 2019
44
Electroacupuncture improves neurogenic bladder dysfunction through activation of NGF/TrkA signaling in a rat model. 38
30592331 2019
45
Comparison of Escherichia coli and Klebsiella pneumoniae Acute Pyelonephritis in Korean Patients. 38
31270992 2019
46
Neurogenic bladder and congenital Zika syndrome. 38
31331807 2019
47
Predictors of low urinary quality of life in spinal cord injury patients on clean intermittent catheterization. 38
30912199 2019
48
Quality of life after spinal cord injury: An overview. 38
31186151 2019
49
Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: A retrospective primary care database study. 38
30924184 2019
50
Comment on the 'Letter to the Editor' related to the article 'Neurogenic bladder in the settings of congenital Zika syndrome: a confirmed and unknown condition for urologists'. 38
31351948 2019

Variations for Neurogenic Bladder

ClinVar genetic disease variations for Neurogenic Bladder:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 EBF3 NM_001005463.3(EBF3): c.512G> A (p.Gly171Asp) single nucleotide variant Pathogenic rs1057519437 10:131755564-131755564 10:129957300-129957300
2 CACNA1A NM_001127221.1(CACNA1A): c.6128C> T (p.Thr2043Met) single nucleotide variant Uncertain significance rs563345694 19:13323262-13323262 19:13212448-13212448
3 COL6A2 NM_001849.3(COL6A2): c.2008A> G (p.Thr670Ala) single nucleotide variant Uncertain significance 21:47545737-47545737 21:46125823-46125823

Expression for Neurogenic Bladder

Search GEO for disease gene expression data for Neurogenic Bladder.

Pathways for Neurogenic Bladder

Pathways related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.32 P2RX2 P2RX1 ERBB3 CHRM2 CACNA1A
2 10.6 PIP5K1C CHRM2

GO Terms for Neurogenic Bladder

Cellular components related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of postsynaptic membrane GO:0099055 8.96 P2RX1 CHRM2
2 integral component of nuclear inner membrane GO:0005639 8.62 P2RX2 P2RX1

Biological processes related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.61 P2RX2 CHRM2 CACNA1A
2 regulation of synaptic vesicle exocytosis GO:2000300 9.46 P2RX1 CHRM2
3 cation transmembrane transport GO:0098655 9.4 P2RX2 P2RX1
4 neuromuscular synaptic transmission GO:0007274 9.37 P2RX2 CACNA1A
5 synaptic transmission, glutamatergic GO:0035249 9.32 P2RX1 CACNA1A
6 response to ATP GO:0033198 9.26 P2RX2 P2RX1
7 regulation of smooth muscle contraction GO:0006940 9.16 P2RX1 CHRM2
8 behavioral response to pain GO:0048266 8.96 P2RX2 CACNA1A
9 purinergic nucleotide receptor signaling pathway GO:0035590 8.62 P2RX2 P2RX1

Molecular functions related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.43 P2RX2 P2RX1 CACNA1A
2 extracellularly ATP-gated cation channel activity GO:0004931 9.16 P2RX2 P2RX1
3 purinergic nucleotide receptor activity GO:0001614 8.96 P2RX2 P2RX1
4 ATP-gated ion channel activity GO:0035381 8.62 P2RX2 P2RX1

Sources for Neurogenic Bladder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....